StarHealing
Article

NCT07898787: what the registered QII confirmatory study says

A plain reading of the registered global QII study: design, endpoints, eligibility, timeline and what a registry entry does not prove.

Registration at a glance

ClinicalTrials.gov lists NCT07898787, Evaluation of a Novel Quantum-Inspired Intervention (QII) for Children With Autism Spectrum Disorder: A Global Confirmatory Study. The lead sponsor is BlissBot, Inc. (industry). The record was first posted on 27 October 2026 and last updated the same day; status is not yet recruiting, with a verified date of October 2026.

Estimated dates in the registry: start February 2027, primary completion February 2028, study completion May 2028. Estimated enrolment is 80 participants. The study is interventional, randomised, parallel-group, with triple masking (participant, investigator, outcomes assessor) and primary purpose listed as treatment. Phase is listed as N/A.

What the study compares

Participants are randomised 1:1 to two parallel arms:

  • QII arm — the proprietary, non-pharmacological, non-invasive, non-contact Quantum-Inspired Intervention protocol delivered remotely by trained practitioners over three months.
  • Waitlist control — the identical intake, profiling and Developmental Report workflow with usual care, but no QII during the study period. The protocol is offered after the primary analysis if the Data Monitoring Committee identifies no safety concerns.

Both arms continue usual care. Efficacy endpoints are assessed by independent licensed clinicians at partner hospitals who are external to the sponsor and intervention team, and who are blinded to allocation.

The five-stage workflow described in the registry

  1. Caregiver intake — structured questionnaires and text, voice or video observations submitted through a secure web portal, covering communication, social responsiveness, emotional stability, sleep and behaviour.
  2. AI-enabled processing — transcription, indexing and fine-grained synthesis into structured developmental profiles. The registry explicitly assigns the AI pipeline an administrative, analytical and coordination support role.
  3. Practitioner review and family alignment — practitioners identify one to two primary developmental priorities in an individualised Developmental Report, which the caregiver reviews and signs off.
  4. QII delivery — a standardised non-contact protocol delivered remotely; no travel or added training burden for the family.
  5. Reassessment — the same intake battery is repeated at the end of month three. Platform profiles are used for planning and documentation only; formal endpoints are assessed independently.

What is measured

  • Primary: Clinical Global Impression–Improvement (CGI-I) for the primary intervention target identified at baseline, rated by a blinded independent clinician on a 7-point scale. Response is defined as a score of 1 (very much improved) or 2 (much improved), assessed at the end of the three-month period.
  • Secondary: change from baseline in the Aberrant Behavior Checklist–Irritability subscale (ABC-I; 15 items, 0–45, higher scores indicate greater irritability), completed by caregivers under a blinded assessor's administration.
  • Safety: adverse events reported at any time through the portal, recorded at scheduled assessments, with an independent Data Monitoring Committee reviewing safety and data integrity.

The registry's stated design assumption is 90% power to detect a 40% CGI-I response rate in the QII arm versus 10% in the waitlist arm, with 40 participants per arm and a two-sided 0.05 test.

Who the registry says can take part

Inclusion: age 5–17 at enrolment; DSM-5 ASD diagnosis confirmed by a qualified clinician and documented for at least one year; a caregiver able to use the web portal in Chinese or English; written guardian consent and child assent where appropriate.

Exclusion: planned new treatment or medication change during the study; unstable medical conditions such as uncontrolled seizures; concurrent participation in another interventional trial; any other condition that, in the investigator's judgement, would interfere with participation or assessment.

What this registration does and does not establish

This is a protocol record, not a results report. No outcome data are posted. The study has not started recruiting. The registry notes that design details may be refined following consultation with regulatory authorities.

Two points are worth stating plainly. First, the AI component is described as analytical support and the intervention is delivered by trained practitioners; it is not presented as an autonomous clinical decision-maker. Second, the trial's existence is not evidence that QII works — it is evidence that a confirmatory study is planned, with blinded independent endpoints and a waitlist control.

For context on the earlier, much smaller records, see the Stage 1 and longitudinal evidence claim.

FAQ

Is the trial recruiting now?

No. The registry lists status as not yet recruiting, with an estimated start of February 2027.

Are results available?

No. The record contains a protocol, endpoints and eligibility criteria, not outcome data.

Is a registry entry peer-reviewed?

No. Registration is a public record of a planned study, not peer review of results.

Does the AI deliver the intervention?

The registry says the AI pipeline transcribes, organises and synthesises caregiver inputs into profiles for clinical review. Trained practitioners deliver the QII protocol, and blinded independent clinicians assess outcomes.

Original source

Summarized from the ClinicalTrials.gov registry record for NCT07898787. Check the registry for the current version and any posted results.